Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axatilimab + olaparib
- Development stage
- Phase 1
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Axatilimab + olaparib is an investigational combination therapy being evaluated for the treatment of metastatic HER2-negative breast cancer in patients with BRCA1/2 or PALB2 mutations. Axatilimab is a humanized monoclonal antibody that targets the colony-stimulating factor 1 receptor (CSF1R), which is expressed on monocytes and macrophages; by inhibiting CSF1R, it aims to deplete or reprogram immunosuppressive tumor-associated macrophages (TAMs) in the tumor microenvironment. Olaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair pathways, leading to synthetic lethality in cancer cells with homologous recombination deficiencies (HRD), such as those with BRCA mutations. The combination is being studied by the Dana-Farber Cancer Institute in the Phase Ib AXALAP trial to investigate whether modulating the myeloid compartment of the tumor microenvironment can overcome resistance or enhance the clinical activity of PARP inhibition.
- Other names
- Axatilimab and Olaparib combinationAxatilimab plus Olaparib
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)PARP3 (Poly(adp-ribose) polymerase 3)
Beyond the preview
Go deeper on axatilimab + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axatilimab + olaparib.